LON:INDVIndivior Share Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Indivior PLC Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add GBX 44.02 -0.42 (-0.95 %) (As of 04/7/2020 04:00 PM ET) Add Compare Share Today's Range 43.20Now: GBX 44.02▼ 4850-Day Range 35.06MA: GBX 44.92▼ 59.4652-Week Range 20.98Now: GBX 44.02▼ 106.40Volume5.32 million shsAverage Volume2.44 million shsMarket Capitalization£322.41 millionP/E Ratio2.45Dividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartInsider TradesHeadlines Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence. The company's product pipeline focuses on treating opioid use disorder, alcohol use disorder, opiate overdose, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy analgesic products that include Temgesic, Burpex, and Buprenex. The company operates in approximately 40 countries worldwide. Indivior PLC was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.Read More Beat the Market (BTM) Rank™ 3.1 Analyst's Opinion Consensus RatingIndivior has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 1 buy rating, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of GBX 71.33, Indivior has a potential upside of 62.0% from its current price of GBX 44.02.Amount of Analyst CoverageIndivior has only been the subject of 2 research reports in the past 90 days. Previous Next 3.4 Community Rank Outperform VotesIndivior has received 549 “outperform” votes. (Add your “outperform” vote.)Underperform VotesIndivior has received 266 “underperform” votes. (Add your “underperform” vote.)Community SentimentIndivior has received 67.36% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Indivior and other stocks. Vote “Outperform” if you believe INDV will outperform the S&P 500 over the long term. Vote “Underperform” if you believe INDV will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldIndivior does not currently pay a dividend.Dividend GrowthIndivior does not have a long track record of dividend growth. Previous Next 3.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Indivior insiders have bought more of their company's stock than they have sold. Specifically, they have bought £20,800 in company stock and sold GBX 0 in company stock. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Indivior are expected to decrease by -100.00% in the coming year, from GBX 5.02 to GBX 0 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Indivior is 2.45, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 11.86.Price to Earnings Ratio vs. SectorThe P/E ratio of Indivior is 2.45, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 20.41.Price to Book Value per Share RatioIndivior has a P/B Ratio of 1.54. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.1Community Rank: 3.4Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 1.3 5 -4 -3 -2 -1 -Overall Beat the Market Rank™2.16 out of 5 stars Industry, Sector and Symbol Stock Exchange LON Industry Drugs - Generic Sub-IndustryN/A SectorMedical Current SymbolLON:INDV Previous Symbol CUSIPN/A CIKN/A Webhttp://indivior.com/ Phone+44-1753-217800Debt Debt-to-Equity Ratio140.19 Current Ratio1.83 Quick Ratio1.70Price-To-Earnings Trailing P/E Ratio2.45 Forward P/E Ratio8.78 P/E GrowthN/A Sales & Book Value Annual Sales£785 million Price / Sales0.41 Cash FlowGBX 143.06 per share Price / Cash Flow0.31 Book ValueGBX 28.60 per share Price / Book1.54Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees915 Outstanding Shares732,408,000Market Cap£322.41 million Next Earnings Date4/30/2020 (Estimated) OptionableNot Optionable Receive INDV News and Ratings via Email Sign-up to receive the latest news and ratings for INDV and its competitors with MarketBeat's FREE daily newsletter. LSE:INDV Rates by TradingView Indivior (LON:INDV) Frequently Asked Questions How has Indivior's stock been impacted by COVID-19 (Coronavirus)? Indivior's stock was trading at GBX 46.21 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, INDV shares have decreased by 4.7% and is now trading at GBX 44.02. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Indivior? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Indivior in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Indivior. When is Indivior's next earnings date? Indivior is scheduled to release its next quarterly earnings announcement on Thursday, April 30th 2020. View our earnings forecast for Indivior. What price target have analysts set for INDV? 4 equities research analysts have issued 12 month price objectives for Indivior's shares. Their forecasts range from GBX 39 to GBX 130. On average, they expect Indivior's share price to reach GBX 71.33 in the next twelve months. This suggests a possible upside of 62.0% from the stock's current price. View analysts' price targets for Indivior. Has Indivior been receiving favorable news coverage? News headlines about INDV stock have been trending very negative on Tuesday, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Indivior earned a news impact score of -3.3 on InfoTrie's scale. They also gave media coverage about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news aboutIndivior. Who are some of Indivior's key competitors? Some companies that are related to Indivior include Cantel Medical (CMD), Ligand Pharmaceuticals (LGND), Glaukos (GKOS), Change Healthcare (CHNG), Tricida (TCDA), Healius (HLS), Summerset Group (SNZ), Concordia International (CXR), Addus Homecare (ADUS), Luminex (LMNX), Myriad Genetics (MYGN), Rhoen Klinikum (RHK), ZEALAND PHARMA/S (ZEAL), Heron Therapeutics (HRTX) and Tabula Rasa HealthCare (TRHC). What other stocks do shareholders of Indivior own? Based on aggregate information from My MarketBeat watchlists, some companies that other Indivior investors own include Futura Medical (FUM), Bigblu Broadband (BBB), Directa Plus (DCTA), Lakehouse (LAKE), Umicore (UMI), Aquila Services Group (AQSG), Benchmark (BMK), Bodycote (BOY), CityFibre Infrastructure (CITY) and Deltex Medical Group (DEMG). Who are Indivior's key executives? Indivior's management team includes the following people: Mr. Shaun Thaxter, CEO & Exec. DirectorMr. Mark Crossley, CFO & Exec. DirectorDr. Christian Heidbreder, Chief Scientific OfficerMr. Ingo Elfering, Chief Information & Innovation OfficerMr. Jason Thompson, VP of Investor Relations What is Indivior's stock symbol? Indivior trades on the London Stock Exchange (LON) under the ticker symbol "INDV." How do I buy shares of Indivior? Shares of INDV and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What is Indivior's stock price today? One share of INDV stock can currently be purchased for approximately GBX 44.02. How big of a company is Indivior? Indivior has a market capitalization of £322.41 million and generates £785 million in revenue each year. Indivior employs 915 workers across the globe. View additional information about Indivior. What is Indivior's official website? The official website for Indivior is http://indivior.com/. How can I contact Indivior? Indivior's mailing address is 103-105 Bath Road, SLOUGH, SL1 3UH, United Kingdom. The specialty pharmaceutical company can be reached via phone at +44-1753-217800. This page was last updated on 4/7/2020 by MarketBeat.com StaffFeatured Article: Google Finance
